These studies examined both clinical outcomes and molecular mechanisms through tumor biopsy analysis, revealing differential effects on HIF-1α and its transcriptional target, carbonic anhydrase IX (CAIX), indicating potential disruption of response to tumor hypoxia following bortezomib treatment [15]. This evidence concerns the gene HIF1A and neoplasm.